NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer


Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center, comments on current NCCN recommendations for the use of prognostic and predictive gene profiling assays to individualize treatment in patients with HR-positive breast cancer.

Related Videos
prostate cancer
Related Content